Genome editing: The road of CRISPR/Cas9 from bench to clinic

Experimental and Molecular Medicine

Volumn 48, Issue 10, 2016, Pages

  Eid, Ayman ^a   Mahfouz, Magdy M ^a  

^a KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CAS9 PROTEIN; CHEMOKINE RECEPTOR CCR5; CRISPR ASSOCIATED PROTEIN; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE;

ANTIVIRAL THERAPY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; DISEASE MODEL; DNA BINDING; DNA END JOINING REPAIR; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; GENE EDITING; GENE THERAPY; GENETIC DISORDER; GENETIC ENGINEERING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; TRANSCRIPTION REGULATION; TUMOR VIRUS; ANIMAL; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PROCEDURES;

ANIMALS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; GENE EDITING; GENETIC THERAPY; HUMANS; TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES; TRANSCRIPTION, GENETIC; ZINC FINGER NUCLEASES;

EID: 85022169948     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2016.111     Document Type: Review

References (110)

1. Sanseau P. Impact of human genome sequencing for in silico target discovery. Drug Discov Today 2001; 6: 316-323.
2. Oetting WS. Impact of next generation sequencing: The 2009 Human Genome Variation Society Scientific Meeting. Hum Mutat 2010; 31: 500-503.
3. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011; 470: 187-197.
4. Hinnen A, Hicks JB, Fink GR. Transformation of yeast. Proc Natl Acad Sci USA 1978; 75: 1929-1933.
5. Scherer S, Davis RW. Replacement of chromosome segments with altered DNA sequences constructed in vitro. Proc Natl Acad Sci USA 1979; 76: 4951-4955.
6. Mansour SL, Thomas KR, Capecchi MR. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes. Nature 1988; 336: 348-352.
7. Mahfouz MM, Li L. TALE nucleases and next generation GM crops. GM Crops 2011; 2: 99-103.
8. Bibikova M, Carroll D, Segal DJ, Trautman JK, Smith J, Kim YG et al. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol 2001; 21: 289-297.
9. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA doublestrand break repair pathway choice. Mol Cell 2012; 47: 497-510.
10. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40: 179-204.
11. Krejci L, Altmannova V, Spirek M, Zhao X. Homologous recombination and its regulation. Nucleic Acids Res 2012; 40: 5795-5818.
12. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 1996; 93: 1156-1160.
13. Pavletich NP, Pabo CO. Crystal structure of a five-finger GLI-DNA complex: new perspectives on zinc fingers. Science 1993; 261: 1701-1707.
14. Bibikova M, Beumer K, Trautman JK, Carroll D. Enhancing gene targeting with designed zinc finger nucleases. Science 2003; 300: 764.
15. Bitinaite J, Wah DA, Aggarwal AK, Schildkraut I. FokI dimerization is required for DNA cleavage. Proc Natl Acad Sci USA 1998; 95: 10570-10575.
16. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010; 11: 636-646.
17. Cathomen T, Joung JK. Zinc-finger nucleases: The next generation emerges. Mol Ther 2008; 16: 1200-1207.
18. Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res 2005; 33: 5978-5990.
19. Rademaker JL, Louws FJ, Schultz MH, Rossbach U, Vauterin L, Swings J et al. A comprehensive species to strain taxonomic framework for xanthomonas. Phytopathology 2005; 95: 1098-1111.
20. Romer P, Hahn S, Jordan T, Strauss T, Bonas U, Lahaye T. Plant pathogen recognition mediated by promoter activation of the pepper Bs3 resistance gene. Science 2007; 318: 645-648.
21. Kay S, Hahn S, Marois E, Hause G, Bonas U. A bacterial effector acts as a plant transcription factor and induces a cell size regulator. Science 2007; 318: 648-651.
22. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science 2009; 326: 1501.
23. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009; 326: 1509-1512.
24. Deng D, Yan C, Pan X, Mahfouz M, Wang J, Zhu JK et al. Structural basis for sequence-specific recognition of DNA by TAL effectors. Science 2012; 335: 720-723.
25. Li L, Atef A, Piatek A, Ali Z, Piatek M, Aouida M et al. Characterization and DNA-binding specificities of Ralstonia TAL-like effectors. Mol Plant 2013; 6: 1318-1330.
26. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010; 186: 757-761.
27. Mahfouz MM, Li L, Shamimuzzaman M, Wibowo A, Fang X, Zhu JK. De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc Natl Acad Sci USA 2011; 108: 2623-2628.
28. Li L, Piatek MJ, Atef A, Piatek A, Wibowo A, Fang X et al. Rapid and highly efficient construction of TALE-based transcriptional regulators and nucleases for genome modification. Plant Mol Biol 2012; 78: 407-416.
29. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011; 29: 143-148.
30. Deng D, Yin P, Yan C, Pan X, Gong X, Qi S et al. Recognition of methylated DNA by TAL effectors. Cell Res 2012; 22: 1502-1504.
31. Mahfouz MM, Piatek A, Stewart CN Jr. Genome engineering via TALENs and CRISPR/Cas9 systems: challenges and perspectives. Plant Biotechnol J 2014; 12: 1006-1014.
32. Ding Q, Lee Y-K, Schaefer EAK, Peters DT, Veres A, Kim K et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013; 12: 238-251.
33. Tesson L, Usal C, Ménoret S, Leung E, Niles BJ, Remy S et al. Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol 2011; 29: 695-696.
34. Aouida M, Piatek MJ, Bangarusamy DK, Mahfouz MM. Activities and specificities of homodimeric TALENs in Saccharomyces cerevisiae. Curr Genet 2014; 60: 61-74.
35. Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013; 12: 238-251.
36. Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology. 2005; 151(Pt 8): 2551-2561.
37. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ et al. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol 2015; 13: 722-736.
38. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007; 315: 1709-1712.
39. Marraffini LA, Sontheimer EJ. CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet 2010; 11: 181-190.
40. Jiang W, Marraffini LA. CRISPR-Cas: new tools for genetic manipulations from bacterial immunity systems. Annu Rev Microbiol 2015; 69: 209-228.
41. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819-823.
42. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE et al. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823-826.
43. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 2012; 109: E2579-E2586.
44. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816-821.
45. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK et al. Highfrequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 2013; 31: 822-826.
46. Tan EP, Li Y, Velasco-Herrera Mdel C, Yusa K, Bradley A. Off-target assessment of CRISPR-Cas9 guiding RNAs in human iPS and mouse ES cells. Genesis 2015; 53: 225-236.
47. Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 2014; 32: 569-576.
48. Aouida M, Eid A, Ali Z, Cradick T, Lee C, Deshmukh H et al. Efficient fdCas9 synthetic endonuclease with improved specificity for precise genome engineering. PLoS ONE 2015; 10: e0133373.
49. Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol 2014; 32: 577-582.
50. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013; 154: 1380-1389.
51. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 2014; 32: 279-284.
52. Koo T, Lee J, Kim JS. Measuring and reducing off-target activities of programmable nucleases including CRISPR-Cas9. Mol Cells 2015; 38: 475-481.
53. Wang X, Wang Y, Wu X, Wang J, Wang Y, Qiu Z et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol 2015; 33: 175-178.
54. Mahfouz MM. RNA-directed DNA methylation: mechanisms and functions. Plant Signal Behav 2010; 5: 806-816.
55. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 2015; 163: 759-771.
56. Swarts DC, Jore MM, Westra ER, Zhu Y, Janssen JH, Snijders AP et al. DNA-guided DNA interference by a prokaryotic Argonaute. Nature 2014; 507: 258-261.
57. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med 2015; 21: 121-131.
58. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genomewide off-target effects. Nature 2016; 529: 490-495.
59. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science 2016; 351: 84-88.
60. Yamano T, Nishimasu H, Zetsche B, Hirano H, Slaymaker IM, Li Y et al. Crystal structure of Cpf1 in complex with guide RNA and target DNA. Cell 2016; 165: 949-962.
61. Dong D, Ren K, Qiu X, Zheng J, Guo M, Guan X et al. The crystal structure of Cpf1 in complex with CRISPR RNA. Nature 2016; 532: 522-526.
62. Fonfara I, Richter H, Bratovic M, Le Rhun A, Charpentier E. The CRISPRassociated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature 2016; 532: 517-521.
63. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med 2015; 21: 121-131.
64. Robert F, Barbeau M, Ethier S, Dostie J, Pelletier J. Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. Genome Med 2015; 7: 93.
65. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003; 23: 5706-5715.
66. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010; 11: 196-207.
67. Trobridge GD, Miller DG, Jacobs MA, Allen JM, Kiem HP, Kaul R et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 2006; 103: 1498-1503.
68. Mahfouz MM, Li L, Piatek M, Fang X, Mansour H, Bangarusamy DK et al. Targeted transcriptional repression using a chimeric TALE-SRDX repressor protein. Plant Mol Biol 2012; 78: 311-321.
69. Piatek A, Ali Z, Baazim H, Li L, Abulfaraj A, Al-Shareef S et al. RNAguided transcriptional regulation in planta via synthetic dCas9-based transcription factors. Plant Biotechnol J 2015; 13: 578-589.
70. Mahfouz MM, Li L. TALE nucleases and next generation GM crops. GM Crop 2011; 2: 99-103.
71. Polstein LR, Perez-Pinera P, Kocak DD, Vockley CM, Bledsoe P, Song L et al. Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE-and CRISPR/Cas9-based transcriptional activators. Genome Res 2015; 25: 1158-1169.
72. Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 2015; 517: 583-588.
73. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 2014; 159: 647-661.
74. Frock RL, Hu J, Meyers RM, Ho YJ, Kii E, Alt FW. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol 2015; 33: 179-186.
75. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013; 31: 827-832.
76. Lin Y, Cradick TJ, Brown MT, Deshmukh H, Ranjan P, Sarode N et al. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res 2014; 42: 7473-7485.
77. O'Geen H, Yu AS, Segal DJ. How specific is CRISPR/Cas9 really? Curr Opin Chem Biol 2015; 29: 72-78.
78. Jo YI, Suresh B, Kim H, Ramakrishna S. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods. Biochim Biophys Acta 2015; 1856: 234-243.
79. Josephs EA, Kocak DD, Fitzgibbon CJ, McMenemy J, Gersbach CA, Marszalek PE. Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage. Nucleic Acids Res 2015; 43: 8924-8941.
80. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 2015; 33: 187-197.
81. Davis KM, Pattanayak V, Thompson DB, Zuris JA, Liu DR. Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nat Chem Biol 2015; 11: 316-318.
82. Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F et al. RNAdirected gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA 2014; 111: 11461-11466.
83. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370: 901-910.
84. Paul DS, Soranzo N, Beck S. Functional interpretation of non-coding sequence variation: concepts and challenges. Bioessays 2014; 36: 191-199.
85. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-3150.
86. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013; 341: 1233151.
87. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161-165.
88. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung and Blood Institute, Crosby J, Peloso GM, Auer PL et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014; 371: 22-31.
89. Wu Y, Zhou H, Fan X, Zhang Y, Zhang M, Wang Y et al. Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells. Cell Res 2015; 25: 67-79.
90. Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 2014; 15: 445-451.
91. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28: 839-847.
92. Jo YI, Kim H, Ramakrishna S. Recent developments and clinical studies utilizing engineered zinc finger nuclease technology. Cell Mol Life Sci 2015; 72: 3819-3830.
93. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014; 32: 551-553.
94. Ali Z, Abulfaraj A, Idris A, Ali S, Tashkandi M, Mahfouz MM. CRISPR/Cas9-mediated viral interference in plants. Genome Biol 2015; 16: 238.
95. Bloom K, Ely A, Mussolino C, Cathomen T, Arbuthnot P. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther 2013; 21: 1889-1897.
96. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids 2014; 3: e186.
97. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011; 475: 217-221.
98. Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S et al. Analysis of offtarget effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res 2014; 24: 132-141.
99. Weber J, Ollinger R, Friedrich M, Ehmer U, Barenboim M, Steiger K et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc Natl Acad Sci USA 2015; 112: 13982-13987.
100. Sanchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 2015; 15: 387-395.
101. Sachdeva M, Sachdeva N, Pal M, Gupta N, Khan IA, Majumdar M et al. CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Ther 2015; 22: 509-517.
102. Genovese P, Schiroli G, Escobar G, Di Tomaso T, Firrito C, Calabria A et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014; 510: 235-240.
103. Peng Y, Clark KJ, Campbell JM, Panetta MR, Guo Y, Ekker SC. Making designer mutants in model organisms. Development 2014; 141: 4042-4054.
104. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L et al. Generation of genemodified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 2014; 156: 836-843.
105. Park CY, Kim DH, Son JS, Sung JJ, Lee J, Bae S et al. Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell 2015; 17: 213-220.
106. Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016; 351: 403-407.
107. Krishan K, Kanchan T, Singh B. Human genome editing and ethical considerations. Sci Eng Ethics 2015; 22: 597-599.
108. Jordan B. The return of germline gene therapy. Med Sci (Paris) 2015; 31: 691-695.
109. Callaway E. UK scientists gain licence to edit genes in human embryos. Nature 2016; 530: 18.
110. Bosley KS, Botchan M, Bredenoord AL, Carroll D, Charo RA, Charpentier E et al. CRISPR germline engineering-The community speaks. Nat Biotechnol 2015; 33: 478-486.